Literature DB >> 22635024

Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.

Yuji Ikeda1, Katsutoshi Oda, Shunsuke Nakagawa, Satsuki Murayama-Hosokawa, Shogo Yamamoto, Shumpei Ishikawa, Linghua Wang, Yutaka Takazawa, Daichi Maeda, Osamu Wada-Hiraike, Kei Kawana, Masashi Fukayama, Hiroyuki Aburatani, Tetsu Yano, Shiro Kozuma, Yuji Taketani.   

Abstract

OBJECTIVE: Synchronous carcinomas in the endometrium and ovaries can be a single primary tumor with metastasis (SPM) or dual primary tumors (DP). Although the prognosis of DP without any metastases is significantly better than that of SPM, pathological diagnosis is difficult in tumors with similar histological features.
MATERIALS AND METHODS: In 10 tumors from 5 patients with synchronous endometrial and ovarian carcinomas, 250K single nucleotide polymorphism arrays were performed. The patients were genetically diagnosed according to the pattern of copy number alterations (CNAs), in addition to microsatellite status and mutational analysis of PIK3CA, PTEN, K-Ras, and CTNNB1.
RESULTS: Of the 5 patients, 3 exhibited identical CNA patterns, including type, loci, and degree of each alteration in the endometrial and ovarian carcinomas. The other 2 exhibited CNAs only in either endometrial or ovarian carcinoma. All 5 tumors had 1 or more genetic mutations in the genes examined. One patient exhibited mutations both in PIK3CA and PTEN at discordant sites between endometrial and ovarian carcinomas, whereas the other 4 exhibited concordant mutations. Overall, 4 of the 5 patients were genetically diagnosed with SPM, and the remaining 1 with DP. The pathological diagnosis was not in agreement with the genetic diagnosis in 4 of the 5 patients.
CONCLUSIONS: Genome-wide genotyping diagnosis may represent a useful approach for distinguishing between SPM and DP in synchronous endometrial and ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635024     DOI: 10.1097/IGC.0b013e31824c6ea6

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Guidelines for the design, analysis and interpretation of 'omics' data: focus on human endometrium.

Authors:  Signe Altmäe; Francisco J Esteban; Anneli Stavreus-Evers; Carlos Simón; Linda Giudice; Bruce A Lessey; Jose A Horcajadas; Nick S Macklon; Thomas D'Hooghe; Cristina Campoy; Bart C Fauser; Lois A Salamonsen; Andres Salumets
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

2.  Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report.

Authors:  Yuji Ikeda; Masanori Yasuda; Tomomi Kato; Yuri Yano; Akira Kurosaki; Kosei Hasegawa
Journal:  Gynecol Oncol Rep       Date:  2015-02-17

3.  Trends and outcomes of women with synchronous endometrial and ovarian cancer.

Authors:  Koji Matsuo; Hiroko Machida; Erin A Blake; Laura L Holman; Bobbie J Rimel; Lynda D Roman; Jason D Wright
Journal:  Oncotarget       Date:  2018-06-19

4.  Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study.

Authors:  Aya Ishizaka; Ayumi Taguchi; Tetsushi Tsuruga; Marie Maruyama; Akira Kawata; Yuichiro Miyamoto; Michihiro Tanikawa; Masako Ikemura; Kenbun Sone; Mayuyo Mori; Kaori Koga; Tetsuo Ushiku; Katsutoshi Oda; Yutaka Osuga
Journal:  BMC Womens Health       Date:  2022-08-05       Impact factor: 2.742

5.  Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.

Authors:  Aki Miyasaka; Katsutoshi Oda; Yuji Ikeda; Osamu Wada-Hiraike; Tomoko Kashiyama; Atsushi Enomoto; Noriko Hosoya; Takahiro Koso; Tomohiko Fukuda; Kanako Inaba; Kenbun Sone; Yuriko Uehara; Reiko Kurikawa; Kazunori Nagasaka; Yoko Matsumoto; Takahide Arimoto; Shunsuke Nakagawa; Hiroyuki Kuramoto; Kiyoshi Miyagawa; Tetsu Yano; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  BMC Cancer       Date:  2014-03-13       Impact factor: 4.430

6.  Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.

Authors:  Yuji Ikeda; Katsutoshi Oda; Hideki Ishihara; Osamu Wada-Hiraike; Aki Miyasaka; Tomoko Kashiyama; Kanako Inaba; Tomohiko Fukuda; Kenbun Sone; Yoko Matsumoto; Takahide Arimoto; Daichi Maeda; Masako Ikemura; Masahi Fukayama; Kei Kawana; Tetsu Yano; Daisuke Aoki; Yutaka Osuga; Tomoyuki Fujii
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.